NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...

BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA ...

Agitation is the third most common neuropsychiatric symptom observed in patients with dementia, with 30% of patients exhibiting these symptoms; the frequency increases to 80% among patients living in ...

BXCL501 is an oral thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to BXCL501 ...

New Haven’s BioXcel Therapeutics unveiled clinical trial results Tuesday showing its experimental anti-agitation drug could successfully and quickly calm patients suffering from dementia. BioXcel said ...

The primary endpoint for the study is the change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component (also known as PEC) score, measured at 2 hours after the first dose.

ATLANTA — With funding for a new trial secured, electroconvulsive therapy (ECT) is gaining ground as a possible treatment for severe agitation and aggression in patients with Alzheimer's disease (AD).

Statistically significant, clinically meaningful, rapid and durable reductions in agitation achieved with the 60 mcg dose as measured by multiple agitation scales BXCL501 was well tolerated with no ...

Agitation associated with dementia affects an estimated 4 million patients in the U.S. Company to host conference call today at 8:30 a.m. ET The TRANQUILITY Phase 1b/2 randomized, placebo controlled, ...